Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 17/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | CCR1 | P32246 | 1/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.49 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12061277 | 1.00 | CCR2 (1.00) | CCR2RAB9ACCR1CCR5CXCR4 | |
| SCHEMBL13006180 | 1.00 | CCR2 (1.00) | CCR2RAB9ACCR1CCR5CXCR4 | |
| SCHEMBL12061252 | 0.99 | CCR2 (0.97) | CCR2RAB9ACCR1CCR5CXCR4 | |
| SCHEMBL1081727 | 0.96 | CCR2 (0.92) | CCR2RAB9ACCR1CCR5CXCR4 | |
| SCHEMBL1064918 | 0.91 | CCR2 (0.84) | CCR2RAB9ACCR1CCR5CXCR4 | |
| SCHEMBL12061292 | 0.91 | CCR2 (0.84) | CCR2RAB9ACCR1CCR5CXCR4 | |
| SCHEMBL12061309 | 0.90 | CCR2 (0.82) | CCR2RAB9ACCR1CCR5CXCR4 | |
| SCHEMBL3107731 | 0.85 | CCR2 (0.74) | CCR2RAB9ACCR1CCR5CXCR4 | |
| SCHEMBL1062410 | 0.82 | CCR2 (0.70) | CCR2RAB9ANPC1 | |
| SCHEMBL1080108 | 0.82 | CCR2 (0.70) | CCR2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497261-B2 | 3-aminocaprolactam compounds for treating inflammatory disorders | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-30 | — | — | US | claimed |
| US-8076323-B2 | Anti-inflammatory agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-12-13 | — | — | US | claimed |
| US-20110003792-A1 | ANTI-INFLAMMATORY AGENTS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2011-01-06 | — | — | US | claimed |
| US-20100292213-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-11-18 | — | — | US | claimed |
| US-7803794-B2 | Anti-inflammatory agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-09-28 | — | — | US | claimed |
| US-7691845-B2 | Anti-inflammatory agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-04-06 | — | — | US | claimed |
| US-20100016286-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-01-21 | — | — | US | claimed |
| US-20080194541-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2008-08-14 | — | — | US | claimed |
| US-20150141460-A1 | Anti-inflammatory Compositions | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2015-05-21 | — | — | US | disclosed |
| US-8853200-B2 | Treatment of rheumatoid arthritis with 3-amino lactam compounds | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| US-8853200-B2 | Treatment of rheumatoid arthritis with 3-amino lactam compounds | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| EP-2401611-B1 | IMPROVED METHODS FOR IDENTIFICATION | CAMBRIDGE ENTPR LTD (GB) | 2013-11-06 | — | — | EP | disclosed |
| US-8497261-B2 | 3-aminocaprolactam compounds for treating inflammatory disorders | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2013-07-30 | — | — | US | disclosed |
| EP-2572716-A1 | Anti-inflammatory Composition | Cambridge Enterprise Limited (GB) | 2013-03-27 | — | — | EP | disclosed |
| US-20100113518-A1 | METHODS OF USING ANTI-INFLAMMATORY COMPOUNDS | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-05-06 | — | — | US | disclosed |
| US-7691845-B2 | Anti-inflammatory agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-7662967-B2 | Anti-inflammatory compounds and compositions | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-02-16 | — | — | US | disclosed |
| US-20100016286-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20090036486-A1 | 3-(2',2'-Dimethylpropanoylamino)tetrahydropyridin-2-one for prevention or treatment of inflammatory disorders, autoimmune diseases | CAMBRIDGE ENTERPRISE LIMITED THE OLD SCHOOLS (GB) | 2009-02-05 | — | — | US | disclosed |
| US-20080194541-A1 | Anti-Inflammatory Agents | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016286-A1 | Anti-Inflammatory Agents | TNF, LTC4S, IL6 | CCR2 54/4885RAB9A 3745/4885CCR1 75/4885 |
| US-20080194541-A1 | Anti-Inflammatory Agents | TNF, IL1RN, FPR1 | CCR2 96/4885RAB9A 2491/4885CCR1 137/4885 |
| US-20150141460-A1 | Anti-inflammatory Compositions | TNF, PTGES2, IL1B | CCR2 94/4885RAB9A 3886/4885CCR1 200/4885 |
| US-20090036486-A1 | 3-(2',2'-Dimethylpropanoylamino)tetrahydropyridin-2-one for prevention or treatment of inflammatory disorders, autoimmune diseases | TNF, NFKBIA, TPMT | CCR2 207/4885RAB9A 3490/4885CCR1 214/4885 |
| US-20100113518-A1 | METHODS OF USING ANTI-INFLAMMATORY COMPOUNDS | TNF, PTGES2, MMP8 | CCR2 133/4885RAB9A 4485/4885CCR1 243/4885 |
| US-20100292213-A1 | Anti-Inflammatory Agents | TNF, IL1RN, IL1R1 | CCR2 121/4885RAB9A 2291/4885CCR1 160/4885 |
| US-20110003792-A1 | ANTI-INFLAMMATORY AGENTS | TNF, LTC4S, PTGS1 | CCR2 45/4885RAB9A 4003/4885CCR1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.